Language: BG BG
← Back to results
Recruiting Phase 2 NCT07224321

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

Phase 2 – studying effectiveness and dosage
Conditions: Type 1 Diabetes Mellitus

Sponsor: Mannkind Corporation

trial.available_in: БГ
Overview
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.
Who can participate
Inclusion Criteria: * Age 10 to \<18 years of age * Clinical diagnosis of stage 3 T1D, per the investigator. Stage 3 is defined as hyperglycemia, meeting ADA glycemic and clinical diagnostic criteria * Able to start the Afrezza-BI regimen within 10 days following T1D diagnosis (day 1 is based on the first insulin injection) if not hospitalized with diabetic ketoacidosis (DKA) and within 10 days of hospital discharge if hospitalized with DKA * Forced Expiratory Volume in One Second (FEV1) \>80.0% of predicted Global Lung Function Initiative (GLI) value * Investigator believes that participant can be expected to follow the study protocol * No medical, psychiatric, psychosocial conditions, or medications being taken that in the investigator's judgment would be a safety concern for participation in the study Exclusion Criteria: * Prior insulin treatment for stage 2 T1D * History of chronic lung disease, such as asthma, or chronic obstructive pulmonary disease, lung cancer, or any other clinically important pulmonary disease (e.g., cystic fibrosis, bronchopulmonary dysplasia) in the judgment of the investigator * Allergy or known hypersensitivity to human regular insulin * Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 3 months prior to screening and/or positive cotinine test for smoking * Positive urine pregnancy test for female subjects of childbearing potential
Interventions
Technosphere Insulin
DRUG
Technosphere Insulin
DRUG
Basal insulin
DRUG
Locations 10
United States (10)
Barbara Davis Center for Diabetes Young Adult Clinic
Aurora , Colorado
Joslin Diabetes Center
Boston , Massachusetts
University of Virginia
Charlottesville , Virginia
NOT_YET_RECRUITING
University of Florida
Gainsville , Florida
NOT_YET_RECRUITING
Baylor College of Medicine
Houston , Texas
NOT_YET_RECRUITING
Indiana University
Indianapolis , Indiana
NOT_YET_RECRUITING
Children's Hospital Los Angeles
Los Angeles , California
NOT_YET_RECRUITING
Yale University
New Haven , Connecticut
NOT_YET_RECRUITING
University of Oklahoma Health Sciences Center
Oklahoma City , Oklahoma
NOT_YET_RECRUITING
University of California San Francisco
San Francisco , California
NOT_YET_RECRUITING
Technical details
Status
Recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
10 Years
Maximum age
17 Years
Healthy volunteers
No
Start date
04.02.2026
Completion date
01.09.2027
Registry ID
NCT07224321
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.